Stem Cell Therapy for TBI: Masahito Kawabori, MD, PhD

Video

The associate professor at Hokkaido University and investigator of STEMTRA also discussed other efforts in stroke, Alzheimer disease, and Parkinson disease.

“I would like physicians to just wait a little longer for the coming of a new treatment which will bring about a new field in neurosurgery. Stem cell therapy is just around the corner. So, I'm really excited to launch this new field of treatments.”

The STEMTRA trial (NCT02416492), a 1-year, double-blind, randomized, surgical sham-controlled, phase 2 trial, recently investigated implantation of allogeneic modified bone marrow-derived mesenchymal stromal/stem cells (MSCs) developed by SanBio, dubbed SB623. Data suggest that implantation of SB623 is well-tolerated and efficacious in treating individuals with traumatic brain injury (TBI).

Among the study’s investigators was Masahito Kawabori, MD, PhD, associate professor, Hokkaido University, who saw that patients treated with SB623 improved by a least squares (LS) mean of 8.3 (standard error [SE], 1.4) at 6 months from baseline on the Fugl-Meyer Motor Scale (FMSS) score compared to an LS mean improvement of 2.3 (SE, 2.5) in the control group. The LS mean difference was 6.0 (95% CI, 0.3–1.8; P = .04) between SB623 and control. A clinically meaningful improvement of ≥10 points on FMSS was reached in 39.1% of the SB623 pooled group versus 6.7% of controls (P = .039).

NeurologyLive reached out to Kawabori to learn more about TBI and the potential of SB623 to allow patients to regain function. Kawabori also discussed trials investigating SB623 for other conditions and his excitement for the emerging field of stem cell therapy.

REFERENCE
Kawabori M, Weintraub AH, Imai H, et al. Cell therapy for chronic TBI: Interim analysis of the randomized controlled STEMTRA trial. Neurology. Published online January 4, 2021. doi: 10.1212/WNL.0000000000011450

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.